SVRA Savara

Savara to Participate in Three Upcoming Investor Conferences

(Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate at the following investor healthcare conferences:

Jefferies London Healthcare Conference

November 16, 2022 at 9:35am PT/ 12:35pm ET / 5:35pm GMT

Corporate Presentation

Waldorf Hilton, London, UK

Piper Sandler 34th Annual Healthcare Conference

November 29, 2022 at 5:00am PT / 8:00am ET

Corporate Presentation

Lotte New York Palace, New York City, NY

Evercore ISI 5th Annual HealthCONx Conference

November 30, 2022 at 10:50am PT / 1:50pm ET

Fireside Chat

Virtual Conference

A webcast of each presentation will be available through the Investors page of Savara’s website at and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at . (Twitter: , LinkedIn: ).

EN
09/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Savara

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 5, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Savara Inc: 1 director

A director at Savara Inc bought 150,000 shares at 2.775USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramo...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)” at the meeting. ATS 2025 Posters Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch